CDTX - Cidara antifungal drug Rezzayo launched in US by partner Melinta

2023-07-31 18:46:32 ET

Cidara Therapeutics ( NASDAQ: CDTX ) said that commercial partner Melinta Therapeutics has launched its recently approved antifungal drug Rezzayo in the US.

Under their commercialization agreement , Cidara received $30M upfront and $20M for Rezzayo's FDA approval earlier this year. Cidara is also eligible to receive up to $410M if certain other milestones are met, along with tiered royalties in the low double digits to mid-teens percentage on US sales. Rezzayo is also known as rezafungin.

Cidara has partnered with Mundipharma for commercialization of the drug in the EU, where it is currently being reviewed by regulators. A decision is expected by the end of the year. Cidara is evaluating possible commercial partners for the drug in Japan.

The biotech company added that it will provide an update on its Cloudbreak Fc conjugate programs, which includes CD388, at an upcoming R&D event.

Cidara has been developing CD388 with Johnson & Johnson's ( JNJ ) Janssen unit for the prevention of influenza A and B in high-risk individuals. Earlier this month, Cidara said the agreement remains intact despite Janssen's decision to scrap development of most of its infectious disease pipeline.

More on Cidara:

• Cidara says J&J development deal for CD388 remains intact
• Cidara Therapeutics joins Russell Microcap
• Cidara gains as FDA grants fast track status for flu candidate

For further details see: